Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection

ZIGNEGO, ANNA LINDA; RAMOS-CASALS, MANUEL; RETAMOZO, SOLEDAD; BRITO-ZERÓN, PILAR; MANGIA, ALESSANDRA; LAMPRECHT, PETER; YOUNOSSI, ZOBAIR M.; TZIOUFAS, ATHANASIOS G.; FERRI, CLODOVEO; CASATO, MILVIA; SAADOUN, DAVID; CACOUB, PATRICE

JOURNAL OF HEPATOLOGY

ELSEVIER SCIENCE BV

Año: 2017 vol. 66 p. 1282 - 1299

0168-8278

LAY SUMMARY? The current therapeutic armamentarium against HCV has been recently expanded with an explosion of new molecules (DAAs) with high virological efficacy? The objective of this international consensus is to provide therapeutic recommendations for HCV patients with extrahepatic manifestations (EHM).? The use of non-antiviral therapeutic approaches should be evaluated according to the type of EHM and severity of the clinical presentation? B cell depletion with rituximab is the established biologic approach to cryoglobulinaemic vasculitis (CV) employed to date.? The efficacy of therapies in EHM patients should be evaluated not only according to the virological response, but also according to the full impact of the other clinical and immunological responses achieved.? Clinical experience of the use of the new DAAs in EHM remains very limited, with less than 100 cases reported in the last 2 years (overwhelmingly in CV patients)